PRESCRIBING ERWINAZE

Click here for Full Prescribing Information.


Selected Risk Information about Erwinaze™ (asparaginase Erwinia chrysanthemi)

CONTRAINDICATIONS: Hx of serious hypersensitivity to Erwinaze, including anaphylaxis; Hx of serious pancreatitis, thrombosis or hemorrhage with prior L-asparaginase therapy.

WARNINGS AND PRECAUTIONS: Discontinue if serious hypersensitivity, including anaphylaxis, OR severe or hemorrhagic pancreatitis occur. Monitor glucose (intolerance may not be reversible); With thrombosis and hemorrhage: discontinue until resolved. Use in pregnant women only if clearly needed. Do not use in lactating women.

COMMON (≥ 1%) ADVERSE REACTIONS: Serious hypersensitivity, including anaphylaxis, pancreatitis, abnormal transaminases, coagulation abnormalities, nausea, vomiting, and hyperglycemia.

Please see full Prescribing Information.


This site is only intended for residents of the United States.

HCP Support Hub

Reimbursement Hotline
and Patient Support

EUSAPharma@AccessMED.com
T: 888-837-4397
F: 866-287-3036


The reimbursement hotline is available for patients, physicians or healthcare provide staff to assist with reimbursement or coverage questions.